# Berberine Prevent Contrast-induced Nephropathy in Patients With Diabetes

Study · id `cardio:ct-nct02808351` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02808351](<https://clinicaltrials.gov/study/NCT02808351>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02808351

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 800 participants.

## Technical summary

Registry record NCT02808351. Randomized; single masking; primary purpose treatment. Start 2016-07 (actual); primary completion 2021-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 800 participants (enrolled count; ClinicalTrials.gov record NCT02808351, source copy `cardio:ctgov-nct02808351-2022-03-29`, retrieved 2026-10-26)
- Started: 2016-07 (actual) (ClinicalTrials.gov record NCT02808351, source copy `cardio:ctgov-nct02808351-2022-03-29`, retrieved 2026-10-26)
- Primary completion: 2021-12 (actual) (ClinicalTrials.gov record NCT02808351, source copy `cardio:ctgov-nct02808351-2022-03-29`, retrieved 2026-10-26)
- Completion: 2021-12 (actual) (ClinicalTrials.gov record NCT02808351, source copy `cardio:ctgov-nct02808351-2022-03-29`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT02808351, source copy `cardio:ctgov-nct02808351-2022-03-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02808351-2022-03-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: Berberine Prevent Contrast-induced Nephropathy in Patients With Diabetes
- Condition: Diabetes Mellitus
- Condition: Chronic Kidney Disease
- Intervention (Drug): Berberine
- Lead sponsor: Nanjing First Hospital, Nanjing Medical University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Nanjing First Hospital, Nanjing Medical University (`cardio:org-nanjing-first-hospital-nanjing-medical-university`)

## Provenance

Content hash: 9f33b5303fd73082e98fda67da003d38092a23c6103f8c7b9a82dc507fe59b16
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
